Paricalcitol + Calcifediol
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Secondary Hyperparathyroidism Due to Renal Causes
Conditions
Secondary Hyperparathyroidism Due to Renal Causes
Trial Timeline
Jan 1, 2014 → Dec 1, 2015
NCT ID
NCT01939977About Paricalcitol + Calcifediol
Paricalcitol + Calcifediol is a approved stage product being developed by AbbVie for Secondary Hyperparathyroidism Due to Renal Causes. The current trial status is completed. This product is registered under clinical trial identifier NCT01939977. Target conditions include Secondary Hyperparathyroidism Due to Renal Causes.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01939977 | Approved | Completed |
Competing Products
20 competing products in Secondary Hyperparathyroidism Due to Renal Causes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP7991 + Cinacalcet + Placebo | Astellas Pharma | Phase 2 | 52 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| KHK7580 + KRN1493 | Kyowa Kirin | Phase 2/3 | 65 |
| KHK7580 | Kyowa Kirin | Phase 1 | 33 |
| KHK7580 | Kyowa Kirin | Phase 3 | 77 |
| KHK7580 | Kyowa Kirin | Phase 3 | 77 |
| Cinacalcet HCl | Kyowa Kirin | Approved | 85 |
| KHK7580 + Cinacalcet Hydrochloride | Kyowa Kirin | Phase 3 | 77 |
| Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493 | Kyowa Kirin | Phase 2 | 52 |
| dirucotide + Placebo | Eli Lilly | Phase 2/3 | 65 |
| dirucotide | Eli Lilly | Phase 2/3 | 65 |
| Paricalcitol + Calcitriol | AbbVie | Pre-clinical | 23 |
| paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo | AbbVie | Phase 3 | 77 |
| Paricalcitol + Darbepoetin alfa | AbbVie | Approved | 85 |
| Birabresib Dose 20 mg | Merck | Phase 1 | 33 |
| Remibrutinib (blinded) + Placebo + Remibrutinib (Open label) | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Approved | 85 |
| BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273 | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |